1. 1. Amosova KM. Porivnialna otsinka antyanhinalnoi efektyvnosti ta perenosymosti livoobertaiuchoho izomeru amlodypinu i oryhinalnoho amlodypinu u khvorykh na esentsialnu arterialnu hipertenziiu. [Comparative assessment of the antianginal efficacy and tolerability of the levorotatory isomer of amlodipine and the original amlodipine in patients with essential arterial hypertension]. Spetsializovanyy medychnyy portal. 2015. https://health-ua.com/article/15521-porvnyalna-otcnka-antigpertenzivno-efektivnost-ta-perenosimost-lvoobertayuc [date access 20.05.2023] (In Ukrainian).
2. 2. Bychko MV. Antahonisty kaltsiiu v likuvanni khvorykh na arterialnu hipertenziiu asotsiiovanu iz ishemichnoiu khvoroboiu sertsia [Calcium antagonists in the treatment of patients with arterial hypertension associated with coronary heart disease]. Uzhhorod: Lira. 2019, p. 248. https://dspace.uzhnu.edu.ua/jspui/handle/lib/47306 [date access 20.05.2023] (In Ukrainian).
3. 3. Sen S, Demir M, Yigit Z, Üresin AY. Efficacy and safety of S-amlodipine 2.5 and 5 mg/d in hypertensive patients who were treatment-naive or previously received antihypertensive monotherapy. J Cardiovasc Pharmacol Ther. 2018;23(4):318-328. doi: 10.1177/1074248418769054.
4. 4. Dalal J, Mohan JC, Iyengar SS et al. S-Amlodipine: an isomer with difference-time to shift from racemic amlodipine. Int J Hypertens. 2018; 2918:8681792. doi: 10.1155/2018/8681792.
5. 5. Lutai MI, Lysenko HF. Efektyvnist preparatu amlodypinu (stamlo) u patsiientiv z ishemichnoiu khvoroboiu sertsia v poiednanni z arterialnoiu hipertenziieiu [The effectiveness of the drug amlodipine (stamlo) in patients with coronary heart disease in combination with arterial hypertension]. Ukr. kardiol. zhurn. 2001; 2: 87-99. (In Ukrainian).